What Side Effects Does Published Tesamorelin Trial Data Document?

Because Tesamorelin raises endogenous growth hormone and downstream IGF-1, its published trial safety data documents effects consistent with that mechanism — injection-site erythema and reactions, arthralgia (joint pain), myalgia (muscle pain), and peripheral edema (fluid retention) were among the most commonly reported findings across the pooled Phase 3 trial population.

The trial literature also specifically monitored glucose metabolism, since growth-hormone-axis stimulation can influence insulin sensitivity — this monitoring was built into the trial design given the known pharmacology of GHRH-class compounds.

This summary reflects what the cited published trial literature reports and is provided for research background only — it is not a complete safety profile, is not medical advice, and REVIVE LAB UAE does not provide dosing or administration guidance for any product it sells.